Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2016

View Archived Issues

Hookipa Biotech initiates first-in-human study of HB-101 vaccine for CMV

Bacillus anthracis capsule conjugate vaccine protects rhesus macaques against inhalational anthrax

Ad-hoc analysis of phase I/II data for lentiviral hemopoietic stem-cell gene therapy

RE-024 shows promise for the treatment of PKAN

New radiological tracer developed for prostate cancer imaging

FDA advisory committee recommends approval of Jardiance in cardiovascular indication

FDA approves Epclusa as pan-genotypic single-tablet regimen for chronic HCV infection

Encouraging results for hNSC transplantation to treat SCI

Celyad reports headline results from CHART-1 phase III study of C-Cure

XOMA starts XOMA-123 phase II study

FDA grants fast track designation to arimoclomol for Niemann-Pick disease type C

Cempra submits solithromycin MAA to EMA

Novel PET radioligand shows promise for measuring brain microglial COX-1

Ablynx to license FOX technology for study of inhaled anti-RSV nanobody

Bio-Path and Thomas Jefferson University sign agreement

AbbVie ends duvelisib collaboration with Infinity Pharmaceuticals

Anthera updates progress of blisibimod and liprotamase programs

Intra-Cellular Therapies begins phase III trial of ITI-007

OmniSeq receives New York CLEP approval for OmniSeq Comprehensive panel

EMA committee recommends granting orphan drug designation to Vicore's C-21 in IPF

European commission grants orphan medicinal product designation to Ultragenyx's burosumab

Two phase III studies of Pfizer's bococizumab meet primary endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...